Article Page

Abstract

The Schrödinger perturbation energy for an arbitrary order N of the perturbation has been presented with the aid of a circular scale of time. The method is of a recurrent character and developed for a non-degenerate quantum state. It allows one to reduce the inflation of terms necessary to calculate known from the Feynman’s diagrammatical approach to a number below that applied in the original Schrödinger perturbation theory in QM/MM rational drug discovery and molecular diversity for the construction of a Circular Scale of Time as a Way of Calculating the Quantum-Mechanical Perturbation Energy Given by the Schrödinger Method towards an anti-alpha-bungarotoxin binding MAP-p6.7 peptide mimetic ligand against nicotinic receptor binding site as a potent snake neurotoxin synthetic antidote.

Keywords

Quantum-Mechanical Perturbation Energy, Circular Scale of Time;QM/MM; rational drug discovery; molecular diversity; construction of a Circular Scale Time; Way of Calculating; Quantum-Mechanical; Perturbation Energy; Given Schrödinger Method; anti-alpha-bungarotoxin; MAP-p6.7; peptide; mimetic; ligand; nicotinic receptor; binding site; snake neurotoxin; synthetic antidote;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) The role of QM/MM in rational drug discovery and molecular diversity for the construction of a Circular Scale of Time as a Way of Calculating the Quantum-Mechanical Perturbation Energy Given by the Schrödinger Method towards an anti-alpha-bungarotoxin binding MAP-p6.7 peptide mimetic ligand against nicotinic receptor binding site as a potent snake neurotoxin synthetic antidote.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available